~ Buy the ILEVRO (nepafenac) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR ILEVRO

All Clinical Trials for ILEVRO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01847638 ↗	Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery	Completed	Bausch & Lomb Incorporated	N/A	2013-04-01	To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
NCT01847638 ↗	Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery	Completed	Melissa Toyos	N/A	2013-04-01	To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
NCT01847638 ↗	Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery	Completed	Melissa Toyos, MD	N/A	2013-04-01	To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
NCT02515045 ↗	Dropless vs. Standard Drops Contralateral Eye Study	Completed	Science in Vision	Phase 4	2015-01-01	To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.
NCT02515045 ↗	Dropless vs. Standard Drops Contralateral Eye Study	Completed	Carolina Eyecare Physicians, LLC	Phase 4	2015-01-01	To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.
NCT02752646 ↗	Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%	Completed	Alcon Research	N/A	2016-04-01	This study will examine the tolerability and toxicity of topically applied Nepafenac 0.3% vs ketorolac 0.5% among patients undergoing cataract surgery.
NCT02752646 ↗	Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%	Completed	MDbackline, LLC	N/A	2016-04-01	This study will examine the tolerability and toxicity of topically applied Nepafenac 0.3% vs ketorolac 0.5% among patients undergoing cataract surgery.

Clinical Trial Conditions for ILEVRO

Condition Name

Condition Name for ILEVRO
Intervention	Trials
Cataract	3
Patient Outcomes	1
Patient Preference	1
Post-Operative Inflammation	1

Condition MeSH

Condition MeSH for ILEVRO
Intervention	Trials
Cataract	4
Inflammation	3
Macular Edema	1
Edema	1

Clinical Trial Locations for ILEVRO

Trials by Country

Trials by Country for ILEVRO
Location	Trials
United States	7

Trials by US State

Trials by US State for ILEVRO
Location	Trials
Minnesota	1
Tennessee	1
Montana	1
Kentucky	1
California	1

Clinical Trial Progress for ILEVRO

Clinical Trial Phase

Clinical Trial Phase for ILEVRO
Clinical Trial Phase	Trials
Phase 4	3
N/A	2

Clinical Trial Status

Clinical Trial Status for ILEVRO
Clinical Trial Phase	Trials
Completed	4
Recruiting	1

Clinical Trial Sponsors for ILEVRO

Sponsor Name

Sponsor Name for ILEVRO
Sponsor	Trials
Bausch & Lomb Incorporated	2
Melissa Toyos	1
Melissa Toyos, MD	1

Sponsor Type

Sponsor Type for ILEVRO
Sponsor	Trials
Other	9
Industry	3